Novartis has to include new risks for anti-cancer wonderdrug Kymriah
Keystone / Georgios Kefalas
The American regulator now requires the Swiss pharma giant to include new risks for its immunotherapy for acute lymphoblastic leukaemia.
This content was published on
2 minutes
Keystone-SDA
The US Food and Drug Administration (FDA) is forcing producers of immunotherapies based on genetically modified autologous T lymphocytes (CAR-T), including Novartis, which pioneered the field with its Kymriah (tisagenlecleucel), to include new risks in the package leaflets accompanying these treatments.
In a publication published on Monday evening, the FDA points out that it has identified new risks of T-cell cancer since the approval of Kymriah at the end of August 2017, which could require hospitalisation or even lead to the death of treated patients. The authority stresses that this is “new safety information” and considers that it applies to all CAR-Ts targeting the BCMA- and CD19 proteins.
More
More
Novartis sets sights on high-value medicines and US market
This content was published on
Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market.
At the end of last year, the regulator announced that it was conducting an investigation into this type of treatment, produced by Novartis as well as Gilead Sciences, Johnson and Johnson and Kite Pharma, among others.
Novartis caused a sensation on August 30, 2017 when it obtained the green light in the US to market a first-ever cellular immunotherapy for acute lymphoblastic leukaemia (ALL). At the time, the price of the treatment was set at $475,000.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Swiss parents rely on savings accounts for their children instead of investment funds
This content was published on
According to the survey, over 60% of parents start saving in the first year of life, and around 10% even before the child is born.
Half the Swiss army’s M113 armoured vehicles rehabilitated
This content was published on
Half of the Swiss army's 248 M113 grenadier armoured vehicles are back on the road after being temporarily decommisioned.
Voters in Zurich reject pay rise for local politicians
This content was published on
Local parliamentarians in Zurich will not receive a pay hike after 53.2% of voters in the city came out against the plan on Sunday.
Minimum wage narrowly rejected in canton Basel Country
This content was published on
The Unia trade union initiative had called for a minimum wage of CHF22 ($24.20) per hour for all employees working in the canton.
Bernese voters accept counter-proposal to solar initiative
This content was published on
In the Swiss canton of Bern, there will still be no solar obligation for roof renovations in the future, but there will be one for large car parks.
This content was published on
Two-thirds of Swiss people feel that cohesion in the country is “rather weak”, according to a study. Some 83% of respondents even felt that the sense of community was declining.
Solothurn voters reject minimum wage of CHF23 per hour
This content was published on
Employees in the Swiss canton of Solothurn will not receive a minimum wage of CHF23 ($25.30) per hour. Voters have clearly rejected a left-wing popular initiative for a minimum wage.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.